[SHANGHAI, China, December 28, 2020] - Genor Biopharma Co Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, announced today that multiple IND applications of GB491 (cyclin-dependent kinase 4/6 inhibitor) are under review by NMPA, including indications for 1L/2L hormone receptor positive / human epidermal growth factor receptor 2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.
About GB491 (CDK4/6)
GB491 (lerociclib), co-developed by a US company G1 therapeutics and Genor Biopharma, is a highly selective oral CDK4/6 inhibitor for breast cancer. Genor in-licensed exclusive rights of GB491 from G1 Therapeutics in APAC ex-JP in June 2020. Based on the latest data published at European Society for Medical Oncology (ESMO) 2020 conference, GB491, comparing to the currently approved CDK4/6 inhibitor in China, palbociclib, has demonstrated better safety profile and could be a potentially best-in-class CDK4/6 drug candidate.
About Genor Biopharma
Genor Biopharma Co. Ltd (“Genor”) is a biopharmaceutical powerhouse focusing on developing and commercializing oncology and autoimmune drugs. Genor has successfully developed drug candidates targeting pathways with blockbuster potentials, encompassing top three oncology targets and five out of the ten bestselling drugs globally. Genor has leveraged primarily in-house capabilities in establishing a pipeline of 15 targeted drug candidates with tremendous commercialization potentials in China that cover both proven and novel biological pathways.
Genor’s leadership team boasts more than 15 years of industry experience on average with proven track record and a well-balanced combination of expertise. Genor currently has more than 400 employees across 3 sites in China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as lab in South San Francisco, US, among which 80% are R&D and clinical specialists